Skip to main content
. 2022 Jan 3;12:773581. doi: 10.3389/fimmu.2021.773581

Table 1.

Characteristics of patients in the TCGA, radiogenomic, and validation cohorts.

Variables TCGA cohort Radiogenomic Cohort Validation cohort
n = 335 n = 120 n = 155
N % N % N %
Age (years)
18-60 194 57.9 80 66.7 137 88.4
>60 141 42.1 40 33.3 18 11.6
Laterality
Left 165 49.3 61 50.8 77 49.7
Right 170 50.7 59 49.2 78 50.3
Race
White 216 64.5 97 80.8 143 92.3
Black or African American 70 20.9 22 18.3 4 2.6
Asian 21 6.3 1 0.8 8 5.2
Other 28 8.4 / / / /
Status
Alive 286 85.4 117 97.5 132 85.2
Dead 49 14.6 3 0.5 21 13.5
Lost 0 0 0 0 2 1.3
OS(years)
≤1 50 14.9 6 5.0 5 3.2
>1 ≤3 151 45.1 50 41.7 21 13.6
>3 ≤5 58 17.3 31 25.8 102 65.8
>5years 70 20.9 30 25.0 27 17.4
Unknown 6 1.8 3 2.5 0 0
Depth of invasion
pT1 70 20.9 48 40.0 / /
pT2 220 65.7 66 55.0 / /
pT3 33 9.9 6 5.0 / /
pT4 12 3.6 0 0 / /
Lymph node metastasis
pN0 166 49.6 63 52.5 / /
pN1 107 31.9 41 34.2 / /
pN2 36 10.7 9 7.5 / /
pN3 21 6.3 6 5.0 / /
pNx 5 1.5 1 0.8 / /
Metastasis
pM0 277 82.7 94 78.3 / /
pM1 6 1.8 0 0 / /
pMx 52 15.5 26 21.7 / /
Stage
I 49 14.6 28 23.3 / /
II 206 61.5 76 63.4 / /
III 69 20.6 16 13.3 / /
IV 6 1.8 0 0 / /
Unknown 5 1.5 0 0 / /
Estrogen receptor status
Positive 206 61.5 99 82.5 88 56.8
Negative 116 34.6 21 17.5 65 41.9
Indeterminate 0 0 0 0 0 0
Unknown 13 3.9 0 0 2 1.3
Progesterone receptor status
Positive 173 51.6 88 73.3 74 47.7
Negative 148 44.2 32 26.7 79 51.0
Indeterminate 1 0.3 0 0 0 0
Unknown 13 3.9 0 0 2 1.3
Human epidermal growth factor receptor 2 status
Positive 60 17.9 13 10.8 47 30.3
Negative 184 54.9 62 51.7 105 67.7
Indeterminate 46 13.7 26 21.7 0 0
Unknown 45 13.4 19 15.8 3 2.0
Neoadjuvant chemotherapy
YES 316 94.3 1 0.8 153 98.7
NO 0 0 119 99.2 2 1.3
Unknown 19 5.7 0 0 0 0